FN1 and melanoma: To investigate the therapeutic efficacy of the nanobody–IL-2 fusions, we employed the B16F10 melanoma model, previously shown to express EIIIB+FN by microscopy, immuno-PET/CT-imaging, and immunohistochemistry (9).